Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
Christianne GroeneveldtPriscilla KindermanDiana J M van den WollenbergRuben L van den OeverJim MiddelburgDana A M MustafaWytske M van WeerdenSjoerd H Van der BurgThorbald van HallNadine van MontfoortPublished in: Journal for immunotherapy of cancer (2021)
Oncolytic reovirus administration represents an effective strategy to induce a local interferon response and strong T-cell influx, thereby sensitizing the tumor microenvironment for subsequent CD3-bsAb therapy. This combination therapy warrants further investigation in patients with non-inflamed solid tumors.